drugset / Trial / NCT03117101
Study of the AL3810 in the Treatment of Advanced Solid Tumor
Phase 1
Completed
17 enrolled
Haihe Biopharma Co., Ltd.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study
Timeline
- Start
- 2014-03
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lucitanib | Small molecule | 5 mg | Oral |
| Subject | Lucitanib | Small molecule | 10 mg | Oral |
| Subject | Lucitanib | Small molecule | 15 mg | Oral |
| Subject | Lucitanib | Small molecule | 20 mg | Oral |